Management of pediatric hypertrophic cardiomyopathy

Angela T Yetman, Brian W. McCrindle

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Purpose of review: As the underlying genetic basis of hypertrophic cardiomyopathy is being characterized, there has been increasing recognition of the wide spectrum and variable evolution of this disease within the pediatric age range. This review outlines recent evidence relevant to the diagnosis, management, and prognosis of hypertrophic cardiomyopathy specific to children and adolescents. Recent findings: Studies of putative causal genes are leading to the discovery of factors affecting the variability of phenotypic expression and possible avenues for new therapies. Nonetheless, the use of genetic testing currently remains for research purposes only. Echocardiography is the primary means for evaluation, with an increasing focus on diastolic performance. Useful prognostic information can be obtained from the safe performance of cardiopulmonary stress testing. Sudden death can occur in children, although the risk factors are likely different than in results. The role and mechanisms for possible ischemia remain controversial, and likely differ between individuals. Activity restrictions are recommended, with medical therapy reserved for those who are symptomatic. For those with important left ventricular outflow obstruction, surgical myectomy may be indicated, with little current role for alcohol septal ablation. Advances in implantable defibrillators now make this therapy feasible in younger children. Summary: There are important differences from adults in the approach to the diagnosis and management of hypertropic cardiomyopathy in children and adolescents. Care regarding prognostication and therapy must be taken given the potential life-long implications.

Original languageEnglish (US)
Pages (from-to)80-83
Number of pages4
JournalCurrent Opinion in Cardiology
Volume20
Issue number2
DOIs
StatePublished - Mar 1 2005

Fingerprint

Hypertrophic Cardiomyopathy
Pediatrics
Ventricular Outflow Obstruction
Implantable Defibrillators
Genetic Testing
Therapeutics
Sudden Death
Cardiomyopathies
Echocardiography
Ischemia
Alcohols
Research
Genes

Keywords

  • Hypertrophic cardiomyopathy
  • Prognosis
  • Sudden death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Management of pediatric hypertrophic cardiomyopathy. / Yetman, Angela T; McCrindle, Brian W.

In: Current Opinion in Cardiology, Vol. 20, No. 2, 01.03.2005, p. 80-83.

Research output: Contribution to journalReview article

Yetman, Angela T ; McCrindle, Brian W. / Management of pediatric hypertrophic cardiomyopathy. In: Current Opinion in Cardiology. 2005 ; Vol. 20, No. 2. pp. 80-83.
@article{a357a26bddfd43658ae680d697cd8c76,
title = "Management of pediatric hypertrophic cardiomyopathy",
abstract = "Purpose of review: As the underlying genetic basis of hypertrophic cardiomyopathy is being characterized, there has been increasing recognition of the wide spectrum and variable evolution of this disease within the pediatric age range. This review outlines recent evidence relevant to the diagnosis, management, and prognosis of hypertrophic cardiomyopathy specific to children and adolescents. Recent findings: Studies of putative causal genes are leading to the discovery of factors affecting the variability of phenotypic expression and possible avenues for new therapies. Nonetheless, the use of genetic testing currently remains for research purposes only. Echocardiography is the primary means for evaluation, with an increasing focus on diastolic performance. Useful prognostic information can be obtained from the safe performance of cardiopulmonary stress testing. Sudden death can occur in children, although the risk factors are likely different than in results. The role and mechanisms for possible ischemia remain controversial, and likely differ between individuals. Activity restrictions are recommended, with medical therapy reserved for those who are symptomatic. For those with important left ventricular outflow obstruction, surgical myectomy may be indicated, with little current role for alcohol septal ablation. Advances in implantable defibrillators now make this therapy feasible in younger children. Summary: There are important differences from adults in the approach to the diagnosis and management of hypertropic cardiomyopathy in children and adolescents. Care regarding prognostication and therapy must be taken given the potential life-long implications.",
keywords = "Hypertrophic cardiomyopathy, Prognosis, Sudden death",
author = "Yetman, {Angela T} and McCrindle, {Brian W.}",
year = "2005",
month = "3",
day = "1",
doi = "10.1097/01.hco.0000153452.45341.36",
language = "English (US)",
volume = "20",
pages = "80--83",
journal = "Current Opinion in Cardiology",
issn = "0268-4705",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Management of pediatric hypertrophic cardiomyopathy

AU - Yetman, Angela T

AU - McCrindle, Brian W.

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Purpose of review: As the underlying genetic basis of hypertrophic cardiomyopathy is being characterized, there has been increasing recognition of the wide spectrum and variable evolution of this disease within the pediatric age range. This review outlines recent evidence relevant to the diagnosis, management, and prognosis of hypertrophic cardiomyopathy specific to children and adolescents. Recent findings: Studies of putative causal genes are leading to the discovery of factors affecting the variability of phenotypic expression and possible avenues for new therapies. Nonetheless, the use of genetic testing currently remains for research purposes only. Echocardiography is the primary means for evaluation, with an increasing focus on diastolic performance. Useful prognostic information can be obtained from the safe performance of cardiopulmonary stress testing. Sudden death can occur in children, although the risk factors are likely different than in results. The role and mechanisms for possible ischemia remain controversial, and likely differ between individuals. Activity restrictions are recommended, with medical therapy reserved for those who are symptomatic. For those with important left ventricular outflow obstruction, surgical myectomy may be indicated, with little current role for alcohol septal ablation. Advances in implantable defibrillators now make this therapy feasible in younger children. Summary: There are important differences from adults in the approach to the diagnosis and management of hypertropic cardiomyopathy in children and adolescents. Care regarding prognostication and therapy must be taken given the potential life-long implications.

AB - Purpose of review: As the underlying genetic basis of hypertrophic cardiomyopathy is being characterized, there has been increasing recognition of the wide spectrum and variable evolution of this disease within the pediatric age range. This review outlines recent evidence relevant to the diagnosis, management, and prognosis of hypertrophic cardiomyopathy specific to children and adolescents. Recent findings: Studies of putative causal genes are leading to the discovery of factors affecting the variability of phenotypic expression and possible avenues for new therapies. Nonetheless, the use of genetic testing currently remains for research purposes only. Echocardiography is the primary means for evaluation, with an increasing focus on diastolic performance. Useful prognostic information can be obtained from the safe performance of cardiopulmonary stress testing. Sudden death can occur in children, although the risk factors are likely different than in results. The role and mechanisms for possible ischemia remain controversial, and likely differ between individuals. Activity restrictions are recommended, with medical therapy reserved for those who are symptomatic. For those with important left ventricular outflow obstruction, surgical myectomy may be indicated, with little current role for alcohol septal ablation. Advances in implantable defibrillators now make this therapy feasible in younger children. Summary: There are important differences from adults in the approach to the diagnosis and management of hypertropic cardiomyopathy in children and adolescents. Care regarding prognostication and therapy must be taken given the potential life-long implications.

KW - Hypertrophic cardiomyopathy

KW - Prognosis

KW - Sudden death

UR - http://www.scopus.com/inward/record.url?scp=15344341336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15344341336&partnerID=8YFLogxK

U2 - 10.1097/01.hco.0000153452.45341.36

DO - 10.1097/01.hco.0000153452.45341.36

M3 - Review article

VL - 20

SP - 80

EP - 83

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 2

ER -